Free Trial

Zealand Pharma A/S Q4 2024 Earnings Report

Zealand Pharma A/S logo
$68.00 +0.69 (+1.03%)
As of 04/3/2025 02:54 PM Eastern

Zealand Pharma A/S EPS Results

Actual EPS
-$0.59
Consensus EPS
-$0.78
Beat/Miss
Beat by +$0.19
One Year Ago EPS
N/A

Zealand Pharma A/S Revenue Results

Actual Revenue
$1.30 million
Expected Revenue
$28.11 million
Beat/Miss
Missed by -$26.81 million
YoY Revenue Growth
N/A

Zealand Pharma A/S Announcement Details

Quarter
Q4 2024
Time
Before Market Opens

Conference Call Resources

Remove Ads

Zealand Pharma A/S Earnings Headlines

Trump Orders 'National Digital Asset Stockpile'
‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more traction
See More Zealand Pharma A/S Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zealand Pharma A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zealand Pharma A/S and other key companies, straight to your email.

About Zealand Pharma A/S

Zealand Pharma A/S (OTCMKTS:ZLDPF), a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.

View Zealand Pharma A/S Profile

More Earnings Resources from MarketBeat